title: Symptomatic and syndromal anxiety and depression.
abstract: The diagnosis of anxiety disorders and major depression can be reliably made based on signs and symptoms. However there are significant limitations to the current system of classification including overlapping criteria, high comorbidity, and the issue of subthreshold syndromes. The literature on treatment response documents that selective serotonin reuptake inhibitors are effective in the treatment of the various anxiety disorders, including when comorbid major depression is present. The literature also suggests that tricyclic antidepressant medications have superior benefits over selective serotonin reuptake inhibitors in major depression. Examination of the functional anatomy of the fear and reward systems may shed light on the underlying processes in the anxiety and depressive disorders. Such an approach points out the importance of addressing avoidance behaviors, which may be more responsive to cognitive behavioral treatments than pharmacological agents.
authors.affiliation: Department of Psychiatry and Behavioral Sciences, Emory University, School of Medicine, Atlanta, Georgia, USA. philninan@learnlink.emory.edu
authors.forename: P T
authors.initials: PT
authors.lastname: Ninan
authors.forename: J
authors.initials: J
authors.lastname: Berger
mesh_terms: D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology; D015928:Cognitive Behavioral Therapy; D003131:Combined Modality Therapy; D015897:Comorbidity; D003865:Major Depressive Disorder / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology; D006801:Humans; D010552:Personality Assessment; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D013577:Syndrome
chemical_list: D000929:Antidepressive Agents, Tricyclic; D017367:Selective Serotonin Reuptake Inhibitors